Abstract | PURPOSE: The perioperative treatment of patients on dual antiplatelet therapy after myocardial infarction, cerebrovascular event or coronary stent implantation represents an increasingly frequent issue for urologists and anesthesiologists. We assess the current scientific evidence and propose strategies concerning treatment of these patients. MATERIALS AND METHODS: RESULTS: CONCLUSIONS: The risk of coronary thrombosis when antiplatelet agents are withdrawn before surgery is generally higher than the risk of surgical hemorrhage when antiplatelet agents are maintained. However, this issue has not yet been sufficiently evaluated in urological patients and in many instances during urological surgery the risk of bleeding can be dangerous. A thorough dialogue among surgeon, cardiologist and anesthesiologist is essential to determine all risk factors and define the best possible strategy for each patient.
|
Authors | Daniel Eberli, Pierre-Guy Chassot, Tullio Sulser, Charles Marc Samama, Jean Mantz, Alain Delabays, Donat R Spahn |
Journal | The Journal of urology
(J Urol)
Vol. 183
Issue 6
Pg. 2128-36
(Jun 2010)
ISSN: 1527-3792 [Electronic] United States |
PMID | 20399452
(Publication Type: Journal Article, Review)
|
Copyright | Copyright 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Platelet Aggregation Inhibitors
|
Topics |
- Acute Coronary Syndrome
(drug therapy)
- Algorithms
- Humans
- Myocardial Infarction
(drug therapy)
- Platelet Aggregation Inhibitors
(therapeutic use)
- Postoperative Hemorrhage
(etiology)
- Risk Factors
- Stents
- Stroke
(drug therapy)
- Urologic Surgical Procedures
|